PROMOTING ACCESS TO AFRICAN RESEARCH

African Journal of Biotechnology

Log in or Register to get access to full text downloads.

Remember me or Register



Expression and characterization of recombinant human serum albumin fusion protein with C-peptide

HL Yang, YY Wei, LP Zhou, JJ Kong

Abstract


C-peptide (CP), connecting the A and B chains in proinsulin, has been considered to possess physiological effects in diabetes. In order to prolong the half-life of CP in vivo, a long acting CP analog [human serum albumin (HSA-CP)] was obtained by direct gene fusion of a single-chain CP to HSA and expressed in host Pichia pastoris GS115. After 72 h of growth on methanol, the recombinant HSA-CP concentration reached a level of 145 mg/L, representing 70% of total proteins in culture supernatant. The recombinant fusion protein was purified by ultra filtration, Q-sepharose fast flow column and Superdex 75 size-exclusion column. It was specifically recognized by the anti-human HSA antibody and CP antibody in Western blotting assay. In vitro, the recombinant HSA-CP can stimulate HEK293 cell proliferation. In Zucker diabetic fatty (ZDF) rats, 12 weeks recombinant HSA-CP treatment could prevent the accumulation of glomerular extracellular matrix, which leads to mesangial expansion and glomerular hypertrophy. The terminal biological half-time of the protein was 3.38±1.87 h after single administration of 500 nmol/kg of HSA-CP in Wister rats. The pharmacokinetic analysis of the protein indicate its promising application in clinical medicine.

Key words: C-peptide, human serum albumin, recombinant fusion protein, Pichia pastoris, bioactivity,biological half-time.




http://dx.doi.org/10.5897/AJB11.643
AJOL African Journals Online